Success Metrics

Clinical Success Rate

90.9%

Based on 10 completed trials

Completion Rate

91%(10/11)

Active Trials

3(20%)

Results Posted

20%(2 trials)

Terminated

1(7%)

Phase Distribution

Ph phase_2

53%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 2Efficacy & side effects

8(61.5%)

Phase 3Large-scale testing

5(38.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(10)

Terminated(1)

Other(1)

Detailed Status

Completed10

Active, not recruiting2

Recruiting1

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

90.9%

Most Advanced

Phase 3

Trials by Phase

Phase 28 (61.5%)

Phase 35 (38.5%)

Trials by Status

completed1067%

active_not_recruiting213%

recruiting17%

terminated17%

unknown17%

Recent Activity

3 active trials

Showing 5 of 15

completedphase_2

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

NCT05834738

unknown

Managed Access Programs for EXV811, Atrasentan

NCT07319585

active_not_recruitingphase_2

Atrasentan in Patients With Proteinuric Glomerular Diseases

NCT04573920

recruiting

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

NCT06952426

active_not_recruitingphase_3

Atrasentan in Patients With IgA Nephropathy

NCT04573478

View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials

NCT05834738Phase 2

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Completed

NCT07319585

Managed Access Programs for EXV811, Atrasentan

Unknown

NCT04573920Phase 2

Atrasentan in Patients With Proteinuric Glomerular Diseases

Active Not Recruiting

NCT06952426

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Recruiting

NCT04573478Phase 3

Atrasentan in Patients With IgA Nephropathy

Active Not Recruiting

NCT02118714Phase 2

Atrasentan Spermatogenesis and Testicular Function

Completed

NCT01858532Phase 3

Study Of Diabetic Nephropathy With Atrasentan

Terminated

NCT01399580Phase 2

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Completed

NCT01356849Phase 2

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Completed

NCT00181558Phase 2

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Completed

NCT00271492Phase 3

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

Completed

NCT00127478Phase 2

A Long Term Safety Study With Atrasentan

Completed

NCT00036556Phase 3

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer